VALIDATED EXECUTIVE ENGAGEMENTS Number of executives repeatedly engaged by snail & email outreach* 
POOL + OUTREACH
| |||||||||||
Easy Growth Opportunities Often Go Unnoticed. Find Your "Low Hanging Fruit".Top Markets for Lupus Therapeutic. |
COVID-19 IMPACT SURVEYMonitor Market Dynamics!Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here. Amid the COVID-19 crisis, the global market for Lupus Therapeutic estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 8.6% over the analysis period 2020-2027.Anti-Inflammatory Drugs, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$1.4 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 8.3% CAGR for the next 7-year period. This segment currently accounts for a 19% share of the global Lupus Therapeutic market. The Lupus Therapeutic market in the U.S. is estimated at US$631.7 Million in the year 2020. The country currently accounts for a 29.59% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$661.6 Million in the year 2027 trailing a CAGR of 8.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR while Rest of European market (as defined in the study) will reach US$661.6 Million by the year 2027. In the global Immunosuppressant Drugs segment, USA, Canada, Japan, China and Europe will drive the 9.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$262.9 Million in the year 2020 will reach a projected size of US$485.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$440.4 Million by the year 2027.We bring years of research experience to this 9th edition of our report. The 130-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, ADMA Biologics, Inc.; Amgen, Inc.; Anthera Pharmaceuticals, Inc.; Bayer Healthcare AG; Biogen, Inc.; Biotest AG; Bristol-Myers Squibb Company; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Immunomedics, Inc.; Kedrion Biopharma, Inc.; LFB Group; MedImmune, LLC; Merck KgaA; Novartis International AG; Pfizer, Inc.; Shire PLC; Takeda Pharmaceuticals Company Ltd.; UCB SA |
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
EXPERT PANEL REGISTRY
We're excited to add you to our Domain Expert Panel! Let's get you started.
*PRIVACY POLICY
YOUR PRIVACY MATTERS TO US!
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.